(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Agenus, Lyft, and Sphere 3D Corp..
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Agenus (AGEN) | 0.93 | 22.08% | 2024-02-14 23:13:06 |
| 2 | Lyft (LYFT) | 19.01 | 15.99% | 2024-02-15 15:16:31 |
| 3 | Sphere 3D Corp. (ANY) | 2.54 | 15.45% | 2024-02-15 04:23:06 |
| 4 | American Superconductor Corporation (AMSC) | 14.44 | 13.61% | 2024-02-15 03:11:05 |
| 5 | Super Micro Computer (SMCI) | 984.47 | 11.8% | 2024-02-15 15:14:40 |
| 6 | Zebra Technologies (ZBRA) | 281.87 | 11.43% | 2024-02-15 15:15:32 |
| 7 | Applied Optoelectronics (AAOI) | 20.88 | 11.24% | 2024-02-14 19:15:06 |
| 8 | Antero Resources (AR) | 23.55 | 11.01% | 2024-02-15 15:52:32 |
| 9 | Aehr Test Systems (AEHR) | 18.78 | 10.34% | 2024-02-14 23:07:06 |
| 10 | NeuroMetrix (NURO) | 3.33 | 9.9% | 2024-02-15 15:50:51 |
The three biggest losers today are Fastly, Sabre Corporation, and Bellicum Pharmaceuticals.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Fastly (FSLY) | 16.36 | -30.5% | 2024-02-15 15:00:39 |
| 2 | Sabre Corporation (SABR) | 3.40 | -22.93% | 2024-02-15 15:14:29 |
| 3 | Bellicum Pharmaceuticals (BLCM) | 0.08 | -17.21% | 2024-02-15 13:23:06 |
| 4 | West Pharmaceutical (WST) | 351.71 | -13.84% | 2024-02-15 15:22:55 |
| 5 | Alimera Sciences (ALIM) | 3.34 | -11.64% | 2024-02-15 01:15:05 |
| 6 | Marathon (MARA) | 26.81 | -8.84% | 2024-02-15 15:13:27 |
| 7 | Upwork (UPWK) | 13.91 | -8.73% | 2024-02-15 15:17:32 |
| 8 | Alnylam Pharmaceuticals (ALNY) | 149.98 | -8.63% | 2024-02-15 15:10:28 |
| 9 | Riot Blockchain (RIOT) | 16.33 | -7.29% | 2024-02-15 15:17:02 |
| 10 | FibroGen (FGEN) | 2.09 | -7.11% | 2024-02-15 15:12:11 |
Winners today
1. Agenus (AGEN) – 22.08%
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
NASDAQ ended the session with Agenus jumping 22.08% to $0.93 on Thursday, following the last session’s upward trend. NASDAQ rose 0.3% to $15,906.17, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Agenus has a trailing twelve months EPS of $-0.81.
Sales Growth
Agenus’s sales growth for the current quarter is 65.8%.
Volume
Today’s last reported volume for Agenus is 18650100 which is 75.37% above its average volume of 10634600.
More news about Agenus.
2. Lyft (LYFT) – 15.99%
Lyft, Inc. operates a peer-to-peer marketplace for on-demand ridesharing in the United States and Canada. The company operates multimodal transportation networks that offer riders personalized and on-demand access to various mobility options. It provides Ridesharing Marketplace, which connects drivers with riders; Express Drive, a flexible car rentals program for drivers; Lyft Rentals that provides vehicles for long-distance trips; and a network of shared bikes and scooters in various cities to address the needs of riders for short trips. The company also integrates third-party public transit data into the Lyft app to offer riders various transportation options. In addition, it offers access to autonomous vehicles; centralized tools and enterprise transportation solutions, such as concierge transportation solutions for organizations; Lyft Pink subscription plans; Lyft Pass commuter programs; first-mile and last-mile services; and university safe rides programs. The company was formerly known as Zimride, Inc. and changed its name to Lyft, Inc. in April 2013. Lyft, Inc. was incorporated in 2007 and is headquartered in San Francisco, California.
NASDAQ ended the session with Lyft jumping 15.99% to $19.01 on Thursday, following the last session’s upward trend. NASDAQ jumped 0.3% to $15,906.17, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Lyft has a trailing twelve months EPS of $-0.88.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -146.23%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Lyft’s EBITDA is 143.35.
Volume
Today’s last reported volume for Lyft is 79343700 which is 381.04% above its average volume of 16493900.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Lyft’s stock is considered to be overbought (>=80).
Sales Growth
Lyft’s sales growth is 3.8% for the ongoing quarter and 13.2% for the next.
Previous days news about Lyft
- Lyft (Lyft) tops Q4 earnings and revenue estimates. According to Zacks on Tuesday, 13 February, "While Lyft has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
- Lyft stock news: hilarious earnings typo sends LYFT to one-year high. According to FXStreet on Wednesday, 14 February, "At the time of writing on Wednesday, Lyft stock has accelerated by 35% to $16.35, while Uber stock has likewise jumped about 14% on the announcement that it will buy back up to $7 billion in stock.", "Still, Lyft stock has gained more than 30% on Wednesday in the aftermath of the basis point flub, and it is hard to argue that initial euphoria regarding the typo did not play some part in Wednesday’s share price spike."
More news about Lyft.
3. Sphere 3D Corp. (ANY) – 15.45%
Sphere 3D Corp. focuses on operating as a carbon neutral bitcoin mining company. It also provides data management solutions through hybrid cloud, cloud, and on-premises implementations directly and through its reseller network and professional services organization. Its products portfolio includes HVE-STACK high density server, which provides computer and storage appliance for the data centers; HVE-VELOCITY, a high availability dual enclosure storage area network that offers reliability and integrity for optimal data storage, protection, and recovery; HVE 3DGFX, a virtual desktop infrastructure solution; HVE STAGE, a server virtualization platform; and HVE VAULT, an appliance designed to handle requirements for backup and replication storage. In addition, it offers self-service and support services. Sphere 3D Corp. is based in Toronto, Canada.
NASDAQ ended the session with Sphere 3D Corp. rising 15.45% to $2.54 on Thursday while NASDAQ jumped 0.3% to $15,906.17.
Earnings Per Share
As for profitability, Sphere 3D Corp. has a trailing twelve months EPS of $-13.58.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -104.07%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Sphere 3D Corp.’s EBITDA is -3.83.
Volume
Today’s last reported volume for Sphere 3D Corp. is 1528470 which is 41.73% below its average volume of 2623320.
Sales Growth
Sphere 3D Corp.’s sales growth for the current quarter is 439.2%.
Moving Average
Sphere 3D Corp.’s value is way above its 50-day moving average of $2.17 and way higher than its 200-day moving average of $1.89.
More news about Sphere 3D Corp..
4. American Superconductor Corporation (AMSC) – 13.61%
American Superconductor Corporation, together with its subsidiaries, provides megawatt-scale power resiliency solutions worldwide. The company operates in two segments, Grid and Wind. The Grid segment offers products and services that enable electric utilities, industrial facilities, and renewable energy project developers to connect, transmit, and distribute power under the Gridtec Solutions brand; and engineering planning services. It provides transmission planning services, which identify power grid congestion, poor power quality, and other risks; grid interconnection solutions for wind farms and solar power plants, power quality systems, and transmission and distribution cable systems; resilient electric grid systems, resilient electric grid systems; D-VAR systems used for controlling power flow and voltage in the AC transmission system; actiVAR system, a fast-switching medium-voltage reactive compensation solution; armorVAR system installed for reactive compensation, power factor correction, loss reduction, utility bill savings, and mitigation of common power quality concerns related to power converter-based generation and load devices; and D-VAR volt var optimization (VVO) that serves the distribution power grid market. This segment also offers ship protection systems, which reduce a naval ship's magnetic signature; and in board power delivery systems, power generation systems, and propulsion systems; and transformers and rectifiers systems. The Wind segment designs wind turbine systems and licenses these designs to third parties under the Windtec Solutions brand. It supplies power electronics and software-based control systems, engineered designs, and support services; and provides customer support services to wind turbine manufacturers. This segment's design portfolio comprises a range of drivetrains and power ratings of 2 megawatts and higher. The company was incorporated in 1987 and is headquartered in Ayer, Massachusetts.
NASDAQ ended the session with American Superconductor Corporation jumping 13.61% to $14.44 on Thursday, following the last session’s upward trend. NASDAQ jumped 0.3% to $15,906.17, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, American Superconductor Corporation has a trailing twelve months EPS of $-0.58.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.67%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 64.8%, now sitting on 135.35M for the twelve trailing months.
Moving Average
American Superconductor Corporation’s worth is way higher than its 50-day moving average of $10.90 and way higher than its 200-day moving average of $8.08.
Sales Growth
American Superconductor Corporation’s sales growth is 17% for the current quarter and 27.6% for the next.
More news about American Superconductor Corporation.
5. Super Micro Computer (SMCI) – 11.8%
Super Micro Computer, Inc., together with its subsidiaries, develops and manufactures high performance server and storage solutions based on modular and open architecture in the United States, Europe, Asia, and internationally. Its solutions range from complete server, storage systems, modular blade servers, blades, workstations, full racks, networking devices, server sub-systems, server management software, and security software. The company provides application-optimized server solutions, rackmount and blade servers, storage, and subsystems and accessories; and server software management solutions, such as Server Management Suite, including Supermicro Server Manager, Supermicro Power Management software, Supermicro Update Manager, SuperCloud Composer, and SuperDoctor 5. In addition, it offers server subsystems and accessories comprising server boards, chassis, power supplies, and other accessories. Further, the company provides server and storage system integration, configuration, and software upgrade and update services; and technical documentation services, as well as identifies service requirements, creates and executes project plans, and conducts verification testing and technical documentation, and training services. Additionally, it offers help desk and on-site product support services for its server and storage systems; and customer support services, including ongoing maintenance and technical support for its products. The company provides its products to enterprise data centers, cloud computing, artificial intelligence, and 5G and edge computing markets. It sells its products through direct and indirect sales force, distributors, value-added resellers, system integrators, and original equipment manufacturers. The company was incorporated in 1993 and is headquartered in San Jose, California.
NASDAQ ended the session with Super Micro Computer rising 11.8% to $984.47 on Thursday, after five consecutive sessions in a row of gains. NASDAQ jumped 0.3% to $15,906.17, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Super Micro Computer has a trailing twelve months EPS of $12.77.
PE Ratio
Super Micro Computer has a trailing twelve months price to earnings ratio of 77.09. Meaning, the purchaser of the share is investing $77.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.92%.
Volume
Today’s last reported volume for Super Micro Computer is 21364100 which is 229.3% above its average volume of 6487680.
Sales Growth
Super Micro Computer’s sales growth for the next quarter is 119.3%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Super Micro Computer’s EBITDA is 76.26.
More news about Super Micro Computer.
6. Zebra Technologies (ZBRA) – 11.43%
Zebra Technologies Corporation, together with its subsidiaries, provides enterprise asset intelligence solutions in the automatic identification and data capture solutions industry worldwide. It operates in two segments, Asset Intelligence & Tracking and Enterprise Visibility & Mobility. The company designs, manufactures, and sells printers, which produce labels, wristbands, tickets, receipts, and plastic cards; dye-sublimination thermal card printers, which produce images which are used for personal identification, access control, and financial transactions; RFID printers that encode data into passive RFID transponders; accessories and options for our printers, including vehicle mounts and battery chargers; stock and customized thermal labels, receipts, ribbons, plastic cards, and RFID tags for printers; and temperature-monitoring labels primarily used in vaccine distribution. It also provides various maintenance, technical support, repair, and managed and professional services; real-time location systems and services; and tags, sensors, exciters, middleware software, and application software; as well as physical inventory management solutions, and rugged tablets and enterprise-grade mobile computing products and accessories. In addition, the company offers barcode scanners, RFID readers, industrial machine vision cameras, and fixed industrial scanners, workforce management solutions, workflow execution and task management solutions, and prescriptive analytics solutions, as well as communications and collaboration solutions. It also provides cloud-based software subscriptions and robotics automation solutions. The company serves retail and e-commerce, manufacturing, transportation and logistics, healthcare, public sector, and other industries through direct sales force, and network of channel partners. The company was founded in 1969 and is headquartered in Lincolnshire, Illinois.
NASDAQ ended the session with Zebra Technologies rising 11.43% to $281.87 on Thursday while NASDAQ rose 0.3% to $15,906.17.
Zebra technologies (zbra) Q4 earnings & revenues decline y/yExiting the fourth quarter, Zebra Technologies had cash and cash equivalents of $137 million compared with $105 million at the end of December 2022. , Zebra Technologies Corporation price-consensus-chart | Zebra Technologies Corporation Quote
Earnings Per Share
As for profitability, Zebra Technologies has a trailing twelve months EPS of $8.95.
PE Ratio
Zebra Technologies has a trailing twelve months price to earnings ratio of 31.49. Meaning, the purchaser of the share is investing $31.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.4%.
More news about Zebra Technologies.
7. Applied Optoelectronics (AAOI) – 11.24%
Applied Optoelectronics, Inc. designs, manufactures, and sells various fiber-optic networking products worldwide. It offers optical modules, lasers, subassemblies, transmitters and transceivers, and turn-key equipment, as well as headend, node, and distribution equipment. The company sells its products to internet data center operators, cable television and telecom equipment manufacturers, and internet service providers through its direct and indirect sales channels. Applied Optoelectronics, Inc. was incorporated in 1997 and is headquartered in Sugar Land, Texas.
NASDAQ ended the session with Applied Optoelectronics rising 11.24% to $20.88 on Thursday, following the last session’s upward trend. NASDAQ rose 0.3% to $15,906.17, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Applied Optoelectronics has a trailing twelve months EPS of $-2.1.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.13%.
Yearly Top and Bottom Value
Applied Optoelectronics’s stock is valued at $20.88 at 16:32 EST, way under its 52-week high of $24.08 and way higher than its 52-week low of $1.60.
More news about Applied Optoelectronics.
8. Antero Resources (AR) – 11.01%
Antero Resources Corporation, an independent oil and natural gas company, engages in the development, production, exploration, and acquisition of natural gas, natural gas liquids (NGLs), and oil properties in the United States. It operates through three segments: Exploration, Development and Production of Natural Gas, NGLs and Oil; Marketing and Utilization of Excess Firm Transportation Capacity; and Midstream Services Through Our Equity Method Investment in Antero Midstream. As of December 31, 2022, the company had approximately 504,000 net acres in the Appalachian Basin; and 174,000 net acres in the Upper Devonian Shale. It also owned and operated 620 miles of gas gathering pipelines in the Appalachian Basin; and 34 compressor stations. The company was formerly known as Antero Resources Appalachian Corporation and changed its name to Antero Resources Corporation in June 2013. Antero Resources Corporation was incorporated in 2002 and is headquartered in Denver, Colorado.
NYSE ended the session with Antero Resources rising 11.01% to $23.55 on Thursday, following the last session’s upward trend. NYSE rose 1.12% to $17,432.75, following the last session’s upward trend on what was an all-around positive trend exchanging session today.
Compared to estimates, antero resources (ar) Q4 earnings: A look at key metricsFor the quarter ended December 2023, Antero Resources (AR Quick QuoteAR – Free Report) reported revenue of $1.19 billion, down 42.7% over the same period last year. , Here is how Antero Resources performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Earnings Per Share
As for profitability, Antero Resources has a trailing twelve months EPS of $2.75.
PE Ratio
Antero Resources has a trailing twelve months price to earnings ratio of 8.56. Meaning, the purchaser of the share is investing $8.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.04%.
Moving Average
Antero Resources’s worth is above its 50-day moving average of $22.30 and below its 200-day moving average of $24.24.
Volatility
Antero Resources’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.00%, a negative 0.58%, and a positive 1.83%.
Antero Resources’s highest amplitude of average volatility was 2.13% (last week), 1.74% (last month), and 1.83% (last quarter).
Sales Growth
Antero Resources’s sales growth is negative 44.2% for the current quarter and negative 18.9% for the next.
More news about Antero Resources.
9. Aehr Test Systems (AEHR) – 10.34%
Aehr Test Systems provides test solutions for testing, burning-in, and semiconductor devices in wafer level, singulated die, and package part form, and installed systems worldwide. Its product portfolio includes FOX-XP and FOX-NP systems that are full wafer contact and singulated die/module test and burn-in systems that can test, burn-in, and stabilize range of devices, including silicon carbide-based and other power semiconductors, 2D and 3D sensors used in mobile phones, tablets and other computing devices, memory semiconductors, processors, microcontrollers, systems-on-a-chip, and photonics and integrated optical devices. The company also offers FOX-CP system, a low-cost single-wafer compact test solution for logic, memory, and photonic devices; FOX WaferPak Contactor, a full wafer contactor capable of testing wafers up to 300mm that enables integrated circuit manufacturers to perform test, burn-in, and stabilization of full wafers on the FOX-P systems. In addition, it provides FOX DiePak Carrier, a reusable temporary package that enables IC manufacturers to perform final test and burn-in of bare die and modules; and FOX DiePak Loader. The company was incorporated in 1977 and is headquartered in Fremont, California.
NASDAQ ended the session with Aehr Test Systems rising 10.34% to $18.78 on Thursday while NASDAQ jumped 0.3% to $15,906.17.
Earnings Per Share
As for profitability, Aehr Test Systems has a trailing twelve months EPS of $0.71.
PE Ratio
Aehr Test Systems has a trailing twelve months price to earnings ratio of 26.45. Meaning, the purchaser of the share is investing $26.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.21%.
More news about Aehr Test Systems.
10. NeuroMetrix (NURO) – 9.9%
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
NASDAQ ended the session with NeuroMetrix rising 9.9% to $3.33 on Thursday, after two successive sessions in a row of losses. NASDAQ jumped 0.3% to $15,906.17, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, NeuroMetrix has a trailing twelve months EPS of $-5.6.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.61%.
Volatility
NeuroMetrix’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.40%, a positive 0.05%, and a positive 2.99%.
NeuroMetrix’s highest amplitude of average volatility was 5.83% (last week), 3.19% (last month), and 2.99% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth declined by 38.9%, now sitting on 6.43M for the twelve trailing months.
More news about NeuroMetrix.
Losers Today
1. Fastly (FSLY) – -30.5%
Fastly, Inc. operates an edge cloud platform for processing, serving, and securing its customer's applications in the United States, the Asia Pacific, Europe, and internationally. The edge cloud is a category of Infrastructure as a Service that enables developers to build, secure, and deliver digital experiences at the edge of the internet. It is a programmable platform designed for web and application delivery. The company offers Compute@Edge; network services to speed up and optimize the delivery of web and application traffic; device detection and geolocation; content delivery network, such as dynamic site acceleration, origin shield, instant purge, surrogate keys, programmatic control, content compression, reliability, and modern protocols and performance services; and streaming solutions and services, including live streaming and media shield. It also provides edge security solutions, such as DDoS protection, next-gen WAF, bot protection, API and ATO protection, advanced rate limiting, and compliance services; transport layer security (TLS) and platform TLS; and origin connect. In addition, the company offers edge applications, such as load balancers and image optimizers; video on demand; and edge delivery services. It serves customers operating in digital publishing, media and entertainment, technology, online retail and education, SaaS, travel and hospitality, and financial services industries. The company was formerly known as SkyCache, Inc. and changed its name to Fastly, Inc. in May 2012. Fastly, Inc. was incorporated in 2011 and is headquartered in San Francisco, California.
NYSE ended the session with Fastly dropping 30.5% to $16.36 on Thursday while NYSE jumped 1.12% to $17,432.75.
Earnings Per Share
As for profitability, Fastly has a trailing twelve months EPS of $-1.03.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.16%.
Volatility
Fastly’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.62%, a positive 0.99%, and a positive 3.59%.
Fastly’s highest amplitude of average volatility was 5.46% (last week), 3.51% (last month), and 3.59% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.8%, now sitting on 487.53M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Fastly’s EBITDA is -75.33.
More news about Fastly.
2. Sabre Corporation (SABR) – -22.93%
Sabre Corporation, through its subsidiaries, provides software and technology solutions for the travel industry worldwide. It operates in two segments, Travel Solutions and Hospitality Solutions. The Travel Solutions segment operates a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, including airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators with a network of travel buyers comprising online and offline travel agencies, travel management companies, and corporate travel departments. This segment also provides a portfolio of software technology products and solutions through software-as-a-service (SaaS) and hosted delivery models to airlines and other travel suppliers. Its products include reservation systems for carriers, commercial and operations products, agency solutions, and data-driven intelligence solutions. The Hospitality Solutions segment provides software and solutions to hoteliers through SaaS and hosted delivery models. Sabre Corporation was incorporated in 2006 and is headquartered in Southlake, Texas.
NASDAQ ended the session with Sabre Corporation falling 22.93% to $3.40 on Thursday, following the last session’s upward trend. NASDAQ jumped 0.3% to $15,906.17, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Sabre Corporation has a trailing twelve months EPS of $-1.84.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 63.2% and 122.2%, respectively.
Sales Growth
Sabre Corporation’s sales growth is 9.6% for the current quarter and 6% for the next.
Volatility
Sabre Corporation’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.25%, a negative 0.16%, and a positive 2.90%.
Sabre Corporation’s highest amplitude of average volatility was 3.94% (last week), 2.54% (last month), and 2.90% (last quarter).
More news about Sabre Corporation.
3. Bellicum Pharmaceuticals (BLCM) – -17.21%
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
NASDAQ ended the session with Bellicum Pharmaceuticals dropping 17.21% to $0.08 on Thursday while NASDAQ rose 0.3% to $15,906.17.
Earnings Per Share
As for profitability, Bellicum Pharmaceuticals has a trailing twelve months EPS of $-0.72.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -148.5%.
Moving Average
Bellicum Pharmaceuticals’s worth is way under its 50-day moving average of $0.13 and way below its 200-day moving average of $0.31.
Volume
Today’s last reported volume for Bellicum Pharmaceuticals is 1796 which is 93.08% below its average volume of 25974.
More news about Bellicum Pharmaceuticals.
4. West Pharmaceutical (WST) – -13.84%
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
NYSE ended the session with West Pharmaceutical falling 13.84% to $351.71 on Thursday, after two sequential sessions in a row of gains. NYSE jumped 1.12% to $17,432.75, following the last session’s upward trend on what was an all-around bullish trend trading session today.
West pharmaceutical services (wst) beats Q4 earnings estimatesWhile West Pharmaceutical has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?
West pharmaceutical (wst) reports Q4 earnings: what key metrics have to sayFor the quarter ended December 2023, West Pharmaceutical Services (WST Quick QuoteWST – Free Report) reported revenue of $732 million, up 3.3% over the same period last year. , Here is how West Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Earnings Per Share
As for profitability, West Pharmaceutical has a trailing twelve months EPS of $7.43.
PE Ratio
West Pharmaceutical has a trailing twelve months price to earnings ratio of 47.34. Meaning, the purchaser of the share is investing $47.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.95%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 2.93B for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jan 29, 2024, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 0.21%.
Yearly Top and Bottom Value
West Pharmaceutical’s stock is valued at $351.71 at 16:32 EST, way under its 52-week high of $415.73 and way higher than its 52-week low of $264.02.
More news about West Pharmaceutical.
5. Alimera Sciences (ALIM) – -11.64%
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
NASDAQ ended the session with Alimera Sciences dropping 11.64% to $3.34 on Thursday, after five consecutive sessions in a row of losses. NASDAQ jumped 0.3% to $15,906.17, following the last session’s upward trend on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Alimera Sciences has a trailing twelve months EPS of $-1.65.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -130.88%.
Yearly Top and Bottom Value
Alimera Sciences’s stock is valued at $3.34 at 16:32 EST, way under its 52-week high of $4.38 and way above its 52-week low of $1.30.
More news about Alimera Sciences.
6. Marathon (MARA) – -8.84%
Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.
NASDAQ ended the session with Marathon dropping 8.84% to $26.81 on Thursday, following the last session’s upward trend. NASDAQ rose 0.3% to $15,906.17, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, Marathon has a trailing twelve months EPS of $-3.08.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.13%.
Yearly Top and Bottom Value
Marathon’s stock is valued at $26.81 at 16:32 EST, way under its 52-week high of $31.30 and way higher than its 52-week low of $5.13.
More news about Marathon.
7. Upwork (UPWK) – -8.73%
Upwork Inc., together with its subsidiaries, operates a work marketplace that connects businesses with various independent professionals and agencies in the United States, India, the Philippines, and internationally. The company's work marketplace provides access to talent with various skills across a range of categories, including sales and marketing, customer service, data science and analytics, design and creative, web, mobile, and software development. Its work marketplace also enables clients to streamline workflows, such as talent sourcing, outreach, and contracting. The company's work marketplace offers access to various functionalities for remote engagements with talent, including communication and collaboration, ability to receive talent invoices through their work marketplace, and payment protection. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Enterprise, and Upwork Payroll, as well as managed and internet escrow agency services. The company was formerly known as Elance-oDesk, Inc. and changed its name to Upwork Inc. in May 2015. Upwork Inc. was incorporated in 2013 and is headquartered in San Francisco, California.
NASDAQ ended the session with Upwork dropping 8.73% to $13.91 on Thursday while NASDAQ rose 0.3% to $15,906.17.
Earnings Per Share
As for profitability, Upwork has a trailing twelve months EPS of $-0.19.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.44%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Upwork’s EBITDA is 67.49.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 325% and 1500%, respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Upwork’s stock is considered to be overbought (>=80).
Moving Average
Upwork’s worth is under its 50-day moving average of $14.48 and way higher than its 200-day moving average of $11.88.
More news about Upwork.
8. Alnylam Pharmaceuticals (ALNY) – -8.63%
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
NASDAQ ended the session with Alnylam Pharmaceuticals dropping 8.63% to $149.98 on Thursday, following the last session’s upward trend. NASDAQ rose 0.3% to $15,906.17, following the last session’s upward trend on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Alnylam Pharmaceuticals has a trailing twelve months EPS of $-4.1.
More news about Alnylam Pharmaceuticals.
9. Riot Blockchain (RIOT) – -7.29%
Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.
NASDAQ ended the session with Riot Blockchain sliding 7.29% to $16.33 on Thursday while NASDAQ rose 0.3% to $15,906.17.
Earnings Per Share
As for profitability, Riot Blockchain has a trailing twelve months EPS of $-1.8.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.88%.
Yearly Top and Bottom Value
Riot Blockchain’s stock is valued at $16.33 at 16:32 EST, way under its 52-week high of $20.65 and way above its 52-week low of $5.16.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Riot Blockchain’s EBITDA is 152.73.
Sales Growth
Riot Blockchain’s sales growth is 42.6% for the present quarter and 41.2% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 68.9% and 30.3%, respectively.
More news about Riot Blockchain.
10. FibroGen (FGEN) – -7.11%
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
NASDAQ ended the session with FibroGen dropping 7.11% to $2.09 on Thursday, following the last session’s upward trend. NASDAQ jumped 0.3% to $15,906.17, following the last session’s upward trend on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FibroGen’s stock is considered to be overbought (>=80).
Earnings Before Interest, Taxes, Depreciation, and Amortization
FibroGen’s EBITDA is 1.67.
Revenue Growth
Year-on-year quarterly revenue growth grew by 155.1%, now sitting on 154.98M for the twelve trailing months.
More news about FibroGen.
Stay up to date with our winners and losers daily report
